EPO and super-EPO: erythropoietins direct neoangiogenesis by cardiac progenitor cells.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 21816360.
- Also identified by DOI 10.1016/j.stem.2011.07.008.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Erythropoietin, the red blood cell-making cytokine, is also a potential cytoprotective agent in heart disease. In this issue of Cell Stem Cell, Hoch et al. (2011) use two heart failure models, including chemotherapeutic cardiotoxicity, to reveal a mechanistic connection between reduced cardiomyocyte production of erythropoietin and neoangiogenesis by cardiac progenitors.
Medical subject headings
- Antineoplastic Agents
- Cell Differentiation
- Endothelial Cells
- Erythropoietin
- Heart Failure
- Myocardium
- Stem Cells